{"id":999820,"date":"2026-09-02T09:25:44","date_gmt":"2026-09-02T13:25:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/"},"modified":"2026-09-02T09:25:44","modified_gmt":"2026-09-02T13:25:44","slug":"edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/","title":{"rendered":"Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n BOULDER, Colo.<\/span>, Sept. 2, 2026<\/span> \/PRNewswire\/ — Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on August 31, 2026, Edgewise granted inducement stock options to purchase a total of 21,000 shares of Edgewise’s common stock and awards of inducement restricted stock units (each, an “RSU award”) covering a total of 10,501 shares of Edgewise’s common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise’s 2024 Inducement Equity Incentive Plan (the “Inducement Plan”).\u00a0<\/p>\n

\n

\n \"Edgewise\n <\/p>\n<\/p><\/div>\n

Each inducement stock option has an exercise price of $41.77 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1\/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee’s continued service.<\/p>\n

Each inducement RSU award shall vest as follows: one-fourth (1\/4th) of the shares subject to each inducement RSU award shall vest on the first, second, third and fourth yearly anniversaries of the grant date, subject to the employee’s continued service.<\/p>\n

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4).\u00a0<\/p>\n

\n About Edgewise Therapeutics<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

Edgewise Therapeutics is a leading biopharmaceutical company focused on developing innovative therapies for serious cardiovascular and cardiometabolic diseases. Leveraging its expertise in integrated muscle physiology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy and heart failure. To learn more, go to\u00a0edgewisetx.com\u00a0<\/a>or follow Edgewise on\u00a0LinkedIn<\/a>,\u00a0X<\/a>,\u00a0Facebook\u00a0<\/a>and\u00a0Instagram<\/a>.<\/p>\n

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302866448.html<\/a><\/p>\n

SOURCE Edgewise Therapeutics<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire BOULDER, Colo., Sept. 2, 2026 \/PRNewswire\/ — Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on August 31, 2026, Edgewise granted inducement stock options to purchase a total of 21,000 shares of Edgewise’s common stock and awards of inducement restricted stock units (each, an “RSU award”) covering a total of 10,501 shares of Edgewise’s common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise’s 2024 Inducement Equity Incentive Plan (the “Inducement Plan”).\u00a0 Each inducement stock option has an exercise price of $41.77 per share, which is equal to the closing price of a share of Edgewise common … <\/p>\n

Continue reading “Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-999820","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BOULDER, Colo., Sept. 2, 2026 \/PRNewswire\/ — Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on August 31, 2026, Edgewise granted inducement stock options to purchase a total of 21,000 shares of Edgewise’s common stock and awards of inducement restricted stock units (each, an “RSU award”) covering a total of 10,501 shares of Edgewise’s common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise’s 2024 Inducement Equity Incentive Plan (the “Inducement Plan”).\u00a0 Each inducement stock option has an exercise price of $41.77 per share, which is equal to the closing price of a share of Edgewise common … Continue reading "Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-02T13:25:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1658885\/Edgewise-Therapeutics-Logo.jpg?id=OA2921982\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules\",\"datePublished\":\"2026-09-02T13:25:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/\"},\"wordCount\":366,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1658885\\\/Edgewise-Therapeutics-Logo.jpg?id=OA2921982\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/\",\"name\":\"Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1658885\\\/Edgewise-Therapeutics-Logo.jpg?id=OA2921982\",\"datePublished\":\"2026-09-02T13:25:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1658885\\\/Edgewise-Therapeutics-Logo.jpg?id=OA2921982\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1658885\\\/Edgewise-Therapeutics-Logo.jpg?id=OA2921982\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/","og_locale":"en_US","og_type":"article","og_title":"Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Market Newsdesk","og_description":"PR Newswire BOULDER, Colo., Sept. 2, 2026 \/PRNewswire\/ — Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on August 31, 2026, Edgewise granted inducement stock options to purchase a total of 21,000 shares of Edgewise’s common stock and awards of inducement restricted stock units (each, an “RSU award”) covering a total of 10,501 shares of Edgewise’s common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise’s 2024 Inducement Equity Incentive Plan (the “Inducement Plan”).\u00a0 Each inducement stock option has an exercise price of $41.77 per share, which is equal to the closing price of a share of Edgewise common … Continue reading \"Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-02T13:25:44+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1658885\/Edgewise-Therapeutics-Logo.jpg?id=OA2921982","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules","datePublished":"2026-09-02T13:25:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/"},"wordCount":366,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1658885\/Edgewise-Therapeutics-Logo.jpg?id=OA2921982","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/","name":"Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1658885\/Edgewise-Therapeutics-Logo.jpg?id=OA2921982","datePublished":"2026-09-02T13:25:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1658885\/Edgewise-Therapeutics-Logo.jpg?id=OA2921982","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1658885\/Edgewise-Therapeutics-Logo.jpg?id=OA2921982"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-11\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=999820"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999820\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=999820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=999820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=999820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}